Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Unsupported off-label chemotherapy in metastatic colon cancer.

de Souza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, Alexander GC.

BMC Health Serv Res. 2012 Dec 29;12:481. doi: 10.1186/1472-6963-12-481.

3.

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.

Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

J Med Econ. 2011;14(5):542-52. doi: 10.3111/13696998.2011.596600. Epub 2011 Jul 6.

PMID:
21728912
4.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

5.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

6.

Evolving treatment of advanced colon cancer.

Segal NH, Saltz LB.

Annu Rev Med. 2009;60:207-19. doi: 10.1146/annurev.med.60.041807.132435. Review.

PMID:
19630571
7.

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).

Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.

J Med Econ. 2013 Dec;16(12):1387-98. doi: 10.3111/13696998.2013.852097. Epub 2013 Oct 25.

PMID:
24102083
8.

Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.

Seal BS, Anderson S, Shermock KM.

J Manag Care Spec Pharm. 2016 Mar;22(3):227-35. doi: 10.18553/jmcp.2016.22.3.227.

9.
10.
11.

Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.

J Natl Cancer Inst. 2014 Feb;106(2):djt371. doi: 10.1093/jnci/djt371.

PMID:
24511107
12.

[A review of chemotherapy for metastatic colon cancer].

Díez-Fernández R, Salinas Hernández P, Girón-Duch C.

Farm Hosp. 2006 Nov-Dec;30(6):359-69. Review. Spanish.

13.

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.

Landsman-Blumberg PB, Carter GC, Johnson BH, Sedgley R, Nicol SJ, Li L, Shankaran V.

Clin Colorectal Cancer. 2014 Sep;13(3):178-84. doi: 10.1016/j.clcc.2014.05.001. Epub 2014 Jun 23.

PMID:
25065655
14.

Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.

Delea TE, Tappenden P, Sofrygin O, Browning D, Amonkar MM, Karnon J, Walker MD, Cameron D.

Eur J Health Econ. 2012 Oct;13(5):589-603. doi: 10.1007/s10198-011-0323-1. Epub 2011 Jun 24.

PMID:
21701940
15.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
16.

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:1-12. doi: 10.3310/hta15suppl1/01. Review.

17.

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.

Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR.

J Geriatr Oncol. 2013 Oct;4(4):302-9. doi: 10.1016/j.jgo.2013.05.001. Epub 2013 Jun 7.

PMID:
24472472
18.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

20.

Biological agents versus chemotherapy in the treatment of colorectal cancer.

Eng C, Shalan N.

Expert Opin Pharmacother. 2006 Jul;7(10):1251-71. Review.

PMID:
16805714

Supplemental Content

Support Center